Key points from article :
Executive team to be led by Hal Barron, MD, until now GlaxoSmithKline’s president of R&D and CSO.
Will co-chair Altos’ board along with:
- Rick Klausner, MD, chief scientist and founder
- Hans Bishop, President and Founder
Aims to reverse disease and aging processes through cellular rejuvenation programming.
Shinya Yamanaka will serve as senior scientific advisor without remuneration.
Will be initially based in the San Francisco Bay Area, San Diego, and Cambridge UK, with “significant” collaborations in Japan.
Bay Area Institute of Science will be led by Peter Walter, PhD.
San Diego Institute will be led by Juan Carlos Izpisua Belmonte, PhD.
Cambridge Institute will be headed by Wolf Reik, MD, whose research has specialized in epigenetic reprogramming of mammalian cells.
Altos seeks to decipher the pathways of cellular rejuvenation programming to create a completely new approach to medicine.
"The goal of Altos will be to reverse the ravages of disease and aging that lead to disability and death, reinvigorating and extending the quality of life."
